Boulder, Colorado — February 10, 2026: The American Journal of Preventive Cardiology (AJPC) has published a landmark multinational study examining sex-based differences in Homozygous Familial Hypercholesterolemia (HoFH) in its first issue under new Editor-in-Chief Dr. Khurram Nasir. The international post-hoc analysis of the ELIPSE open-label extension study provides critical insights into LDL-C burden, treatment response, and sex-specific disease dynamics in one of the most severe inherited lipid disorders, reinforcing the journal’s commitment to advancing inclusive preventive cardiology science.
Science Significance
Homozygous Familial Hypercholesterolemia is a rare genetic disorder marked by extremely elevated LDL cholesterol and accelerated cardiovascular risk, often manifesting early in life. The newly published study evaluated male and female HoFH patients treated with evinacumab, an ANGPTL3 inhibitor, to assess baseline disease characteristics and therapeutic response. Investigators identified significantly higher baseline LDL-C levels in females compared to males, an observation reported for the first time in this population. Importantly, treatment with evinacumab produced clinically meaningful LDL-C reductions across both sexes over 24 weeks, validating the therapy’s lipid-lowering efficacy while highlighting biologic variability. These findings deepen scientific understanding of sex-linked lipid metabolism, genetic expression, and therapeutic pharmacodynamics in ultra-rare cardiovascular disease.
Regulatory Significance
Sex-disaggregated clinical evidence is increasingly critical within regulatory science, trial design, and therapeutic evaluation frameworks. Findings from the ELIPSE extension analysis underscore the importance of integrating sex-based stratification in rare disease trials, particularly where baseline risk and biomarker burden differ. Regulatory authorities globally are emphasizing inclusive datasets to ensure equitable safety and efficacy assessment across demographic groups. Evidence demonstrating differential LDL-C burden and treatment response may inform future labeling considerations, dosing strategies, and clinical endpoint evaluation for lipid-lowering biologics and gene-targeted therapies in HoFH populations.
Business Significance
Advertisement
For the cardiovascular therapeutics ecosystem, the study strengthens the clinical and commercial value proposition of ANGPTL3-targeted therapies and precision lipid management platforms. Enhanced understanding of treatment response variability supports market differentiation, payer engagement, and evidence-driven adoption of advanced lipid-lowering biologics. Pharmaceutical sponsors developing therapies for rare dyslipidemias can leverage sex-based outcomes data to refine clinical positioning, post-market evidence generation, and lifecycle management strategies. The publication also reinforces the role of high-impact journals like AJPC in shaping translational science visibility and therapeutic innovation narratives.
Patients’ Significance
For patients living with HoFH—a condition associated with premature atherosclerosis, early cardiac events, and limited treatment options—the study offers meaningful clinical insight. Identification of higher LDL-C burden in females may support earlier intervention, personalized monitoring, and tailored therapeutic escalation. Demonstrated LDL-C reduction with evinacumab across both sexes reinforces access to effective biologic therapies capable of mitigating cardiovascular risk in genetically predisposed populations. The research advances patient-centered care by promoting more precise, equitable treatment frameworks in rare lipid disorders.
Policy Significance
The study’s findings contribute to broader healthcare policy priorities centered on inclusive clinical research, rare disease equity, and cardiovascular prevention strategy. Editorial commentary accompanying the publication calls for stronger representation of women in cardiovascular trials, emphasizing that sex-based analyses enhance generalizability and treatment equity. Policymakers and research sponsors are increasingly prioritizing funding and regulatory incentives that ensure diverse patient inclusion, biomarker transparency, and evidence-based preventive cardiology frameworks capable of addressing population-specific risk disparities.
The publication of this multinational HoFH analysis marks a pivotal advancement in sex-specific cardiovascular genetics and lipid therapeutics research. By uncovering previously unrecognized disparities in LDL-C burden while validating biologic treatment efficacy, the study reinforces the importance of inclusive science in rare disease cardiology. As preventive cardiology continues evolving toward precision medicine, such evidence will play a central role in shaping clinical guidelines, regulatory frameworks, and equitable therapeutic innovation.
Source: The American Society for Preventive Cardiology press release
